Advances in cancer immunotherapy.
Ockert
D
D
Institute for Immunology, Medical Faculty, Technical University of Dresden, Germany. ockert@rcs.urz.tu-dresden.de
Schmitz
M
M
Hampl
M
M
Rieber
E P
EP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D002678:Chimera; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D004285:Dogs; D015316:Genetic Therapy; D020350:Graft vs Tumor Effect; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D016219:Immunotherapy, Adoptive; D007938:Leukemia / Q000628:therapy; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D009369:Neoplasms / Q000628:therapy*; D016879:Salvage Therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D016207:Cytokines; D018076:DNA, Complementary; D018796:Immunoconjugates